Tamoxifen + Placebo + Tamoxifen (open label)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bleeding
Conditions
Bleeding, Implants, Breakthrough Bleeding
Trial Timeline
Jan 20, 2017 → Jun 5, 2019
NCT ID
NCT02903121About Tamoxifen + Placebo + Tamoxifen (open label)
Tamoxifen + Placebo + Tamoxifen (open label) is a approved stage product being developed by Merck for Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT02903121. Target conditions include Bleeding, Implants, Breakthrough Bleeding.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02903121 | Approved | Completed |
Competing Products
20 competing products in Bleeding